Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Abbisko Announces $123 Million Financing for Cancer Portfolio

publication date: Jan 8, 2021

Abbisko Therapeutics of Shanghai completed a $123 million Series D financing to develop its portfolio of 12 oncology and one diabetes candidates that it hopes will be best-in-class treatments. The company's two lead products are a small molecule FGFR4 inhibitor for hepatocellular carcinoma and a CSF1R inhibitor for solid tumors. The D round was led by The Carlyle Group, with leading investors Warburg Pincus, OrbiMed, Lake Bleu Capital and one unnamed firm. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital